Comparing complication rates in cataract surgery with different pre-operative treatments

Prospective Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative Standard of Care

Phase1; Phase2 Interventional The Eye Centers of Racine and Kenosha · NCT06681688

This study tests if a new combination of eye treatments before cataract surgery can lower the risk of complications compared to standard care.

Quick facts

PhasePhase1; Phase2
Study typeInterventional
Enrollment94 (estimated)
Ages18 Years and up
SexAll
SponsorThe Eye Centers of Racine and Kenosha Academic / other
Locations2 sites (Venice, Florida and 1 other locations)
Trial IDNCT06681688 on ClinicalTrials.gov

What this trial studies

This multicenter, randomized study evaluates the complication rates in patients undergoing bilateral cataract extraction. Participants will have one eye treated with a combination of pre-operative NSAIDs, OMIDRIA, and subconjunctival triamcinolone acetonide, while the fellow eye will receive standard of care treatments. The study aims to assess the effectiveness of the new treatment regimen compared to traditional methods in reducing postoperative complications. Patients will be monitored throughout the study for adherence to treatment and outcomes.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years old who are undergoing bilateral cataract surgery and are at higher risk for postoperative complications.

Not a fit: Patients undergoing cataract surgery combined with other procedures or those with glaucoma may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved postoperative outcomes and reduced complication rates for cataract surgery patients.

How similar studies have performed: Other studies have shown promising results with similar approaches, indicating potential for success in this trial.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult participants \> 18 years of age undergoing bilateral cataract surgery
* Able to provide written informed consent prior to any study related procedure
* Able and willing, as assessed by the Investigator, to follow study instructions, complete study assessments, comply with the protocol, and attend study visits for the duration of the study
* Patients deemed to be "higher risk" for postoperative complications (e.g., well-controlled diabetes (HbA1c ≤7.0), history of uveitis, history of retinal vein occlusion, history of epiretinal membrane, history of vitreomacular traction, evidence of posterior synechiae, etc.) MAY be enrolled provided there has been no evidence of active disease or treatment in the prior 12 months
* Participants who do not meet the exclusion criteria may be enrolled.

Exclusion Criteria:

* Cataract surgery combined with any other procedure (e.g., glaucoma, retina, etc.)
* Glaucoma patients or known steroid responders
* Oral anti-inflammatory medications to treat a systemic disease (exceptions to this include 81 mg aspirin, ibuprofen for headache, etc.)
* Intraocular injection within 6 months
* Any prior ocular implant
* Diagnosis of retinal thickening in the study eye within 12 months of enrollment
* Inability to provide informed consent
* Participation in another clinical trial

Where this trial is running

Venice, Florida and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions CataractOMIDRIA
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.